About Cancer Genetics
Cancer Genetics, Inc. is engaged in the field of personalized medicine, enabling precision medicine in the field of oncology through its diagnostic products and services, and molecular markers. The Company develops, commercializes and provides molecular- and biomarker-based tests and services that enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor and inform cancer treatment, and enable biopharmaceutical companies engaged in oncology trials to select candidate populations and manage adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics. It has a range of disease-focused oncology testing portfolio. Its molecular- and biomarker-based diagnostic services are provided for three sectors: cancer centers and hospitals, biotechnology and biopharmaceutical companies, and the research community.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Medical Laboratories & Research
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: CGIX
- Previous Close: $2.45
- 50 Day Moving Average: $2.12
- 200 Day Moving Average: $1.81
- 52-Week Range: $18,887,000.00 - $1.10
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -4.54
- P/E Growth: -0.06
- Market Cap: $46.27M
- Outstanding Shares: 18,887,000
- Beta: 1.44
- Net Margins: -74.07%
- Return on Equity: -63.26%
- Return on Assets: -40.91%
Companies Related to Cancer Genetics:
- Debt-to-Equity Ratio: 0.12%
- Current Ratio: 2.50%
- Quick Ratio: 2.50%
What is Cancer Genetics' stock symbol?
Cancer Genetics trades on the NASDAQ under the ticker symbol "CGIX."
Where is Cancer Genetics' stock going? Where will Cancer Genetics' stock price be in 2017?
4 equities research analysts have issued 12 month price targets for Cancer Genetics' stock. Their predictions range from $6.00 to $15.00. On average, they anticipate Cancer Genetics' stock price to reach $9.00 in the next year.
When will Cancer Genetics announce their earnings?
Cancer Genetics is scheduled to release their next quarterly earnings announcement on Wednesday, March, 8th 2017.
Who owns Cancer Genetics stock?
Cancer Genetics' stock is owned by a number of of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (1.64%). Company insiders that own Cancer Genetics stock include Edward J Sitar, Geoffrey E Harris, John Pappajohn, Panna Sharma and Raju SK Chaganti.
Who bought Cancer Genetics stock? Who is buying Cancer Genetics stock?
Cancer Genetics' stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. Company insiders that have bought Cancer Genetics stock in the last two years include Edward J Sitar, Geoffrey E Harris, John Pappajohn and Panna Sharma.
How do I buy Cancer Genetics stock?
Shares of Cancer Genetics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Cancer Genetics stock cost?
One share of Cancer Genetics stock can currently be purchased for approximately $2.45.